|
|
|
市場調查報告書
全球的分子診斷市場
Molecular Diagnostics
|
全球的分子診斷市場 是由出版商Global Industry Analysts, Inc.在2010年10月所出版的。
這份英文市場調查報告書包含Pages: 659 價格從美金4500起跳。
本報告書內容包括:全球的分子診斷市場的分析、醫療診斷市場的概要和產品概要、分子診斷的應用趨勢、產品開發和今後的展望、各國市場分類的趨勢、加入企業的介紹、內容綱要摘記如下:
第1章 介紹、方法論、產品定義
第2章 業界概要
- 全球市場展望
- 分子診斷
- 目前的未來分析
- 成長機會
- 市場加入者的機會
- 新的應用領域
- 自動化系統
- 感染病檢查促進診斷市場
- 未來趨勢
第3章 醫療診斷市場的展望
第4章 競爭趨勢
第5章 市場的趨勢和課題
第6章 產品・技術概要
第7章 分子診斷的應用領域
第8章 產品開發和引進
第9章 近年的產品引進
第10章 近年的業界活動
第11章 近年的企業活動
第12章 加入企業
第13章 全球市場的展望
第14章 美國
第15章 加拿大
第16章 日本
第17章 歐洲
第18章 亞太地區
第19章 其他地區
競爭介紹：101家（包含事業部／子公司：121家）
Abstract
This report analyzes the worldwide markets for Molecular Diagnostics in US$
million by the following segments: Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening. The report provides separate
comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and
Rest of World. Annual estimates and forecasts are provided for the period 2007
through 2015. A seven-year historic analysis is also provided for these
markets. The report profiles 101 companies including many key and niche
players such as Abbott Laboratories, Abbott Molecular, Applera Corporation,
Celera, Biomerieux, CytoCore Inc., ELITech Group, GE Healthcare, Gen-Probe
Inc., Genzyme Corporation, Genzyme Genetics, MiraiBio, Inc., Novartis Vaccines
& Diagnostics, Inc., QIAGEN N. V, Quest Diagnostics, Inc., Roche Diagnostics,
Siemens Healthcare Diagnostics, and Tecan Group Ltd. Market data and analytics
are derived from primary and secondary research. Company profiles are mostly
extracted from URL research and reported select online sources.
Table of Contents
1. INTRODUCTION, METHODOLOGY &PRODUCT DEFINITIONS 1
- Study Reliability and Reporting Limitations1
- Disclaimers2
- Data Interpretation & Reporting Level3
- Quantitative Techniques & Analytics3
- Product Definitions and Scope of Study3
- Infectious Diseases Testing4
- Pharmacogenomics4
- Cancer Screening4
2. INDUSTRY OVERVIEW 5
- Global Market Outlook5
- Molecular Diagnostics - The Fastest Growing MedicalDiagnostic Technology5
- Current and Future Analysis5
- Growth Opportunities Abound Molecular Diagnostics Arena6
- Market for Molecular Diagnostics - An Introduction6
- Opportunities Galore for Market Participants7
- New Applications Hold Promising Potential7
- Automated Systems - Prime Target7
- Infectious Disease Testing Drives the Diagnostics Market8
- The Future in Store8
3. A REVIEW OF MEDICAL DIAGNOSTICSMARKET 9
- Clinical Diagnostics Industry - Trends and Tendencies9
- Table 1: Worldwide In Vitro Diagnostics (IVD) Market by Major Players
(2009) -Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott
Laboratories, Ortho/ Lifescan, Bayer/Siemens, Beckman Coulter,
BectonDickinson, Dade Behring/Siemens, BioMerieux, Bio-Rad,
- and Others (includes corresponding Graph/Chart)10
- Table 2: Worldwide In Vitro Diagnostics (IVD) Market (2008)- Percentage
Breakdown by Value Sales for Immunochemistry, Diabetes, Clinical Chemistry,
Point-of-care testing,Molecular Diagnostics, Hematology, Coagulation,and
Others (includes corresponding Graph/Chart)10
- Table 3: Worldwide Molecular Diagnostics Market byLeading Players (2006 -
A Recent Past Perspective) -Market Share Breakdown by Value Sales for Roche
Diagnostics, Chiron, Bayer Diagnostics, GenProbe,Abbott Laboratories, Becton
Dickinson, and Others(includes corresponding Graph/Chart)11
- Diagnostic Tests - Classification11
- Table 4: Worldwide Genetic Testing Market byLeading Players (2006 - A
Recent Past Perspective) -Market Share Breakdown by Value Sales for Roche
Diagnostics/Affymetrix, Abbott Laboratories, Bio-Rad Laboratories, and Others
(includes corresponding Graph/Chart)12
- Nucleic Acid Diagnostics Market - An Overview12
- Molecular Diagnostics - Growth Drivers13
- Molecular Diagnostics - A Replacement and EnablingTechnology14
- Molecular Diagnostics for Lymphoid Malignancies14
4. COMPETITIVE DYNAMICS IN THEMOLECULAR DIAGNOSTICS MARKET 15
- Key Players and Their Technologies15
- The Top Tier15
- Mid-Sized and Small Companies15
5. MARKET TRENDS & ISSUES 17
- Market Consolidations on the Way to Integrate in Vivoand in Vitro
Diagnostics17
- Global Molecular Diagnostics on High Growth Curve17
- Pharmaceutical Firms Carving Their Niche in MolecularDiagnostic Market17
- Towards Tailoring the Right Treatment for the RightDisease17
- Disease-Specific Molecular Diagnostics to DeliverImproved Clinical
Outcomes18
- Molecular Diagnostics and Intellectual Property18
- Business Opportunities in the Offing18
- Challenges Facing the Molecular Diagnostic Market19
- Medical Training and Practice Challenges19
- Shortcomings to Overcome20
- Limited Reimbursements by Third Party Payers -A Stumbling Block20
- Hurdles All the Way for Companies Eyeing MolecularDiagnostics20
- Product Marketing - Key to Commercial Success21
- Integration of Molecular Diagnostics into Therapeutics21
- Molecular Diagnostics - Moving from Centralization toDecentralization22
- Migrating to Decentralized Format22
- Going Ahead with Decentralization23
6. PRODUCT & TECHNOLOGY OVERVIEW 24
- Molecular Diagnostics - Definition & Scope24
- Molecular Diagnostics - Impact on Healthcare24
- Utility of Molecular Diagnostic Tests25
- Background of Molecular Diagnostics25
- Major Molecular Diagnostics Products25
- Major Test Launches in Molecular Diagnostics in theRecent Past26
- Unabated Developments in Molecular DiagnosticsTechnology26
- Signal Amplification Technologies27
- PCR - New Developments27
- Major Applications of Real-Time PCR27
- Quantitative Real-Time PCR for Molecular Diagnostics27
- Signal Detection and Quantification28
- Quantitative Real-Time RT-PCR Analysis28
- Applications of Quantitative Real-Time PCR Analysis28
- Non-PCR Methods28
- Other Signal Amplification Technologies29
- DNA Probe Based Products29
- Direct Detection of Specific Nucleic Acid Sequences29
- Nucleic Acid Amplification and Detection29
- DNA Sequencing and Gene Detection30
- Arrays of Immobilized Probes (DNA Chips) inGene Detection30
- RNA Diagnostics31
- Complementary Molecular Diagnostic Technologies31
- Fluorescent in situ hybridization (FISH)31
- DNA Biochips / Microarrays32
- Biosensors33
- Proteomic Technologies for Molecular Diagnostics33
- Nanotechnology for Molecular Diagnostics33
- Technologies on the Anvil34
- Haplotype Analysis - A Distant Possibility34
- Chronic Multi-Gene Defects Now Diagnosable34
7. AN INSIGHT INTO APPLICATIONS OFMOLECULAR DIAGNOSTICS 35
- Infectious Diseases Testing35
- Activity in the Field35
- Identifying Multidrug Resistance36
- Infectious Disease Treatment Monitoring36
- Other Infectious Diseases Applications36
- Genetic Disease Testing Applications36
- Pharmacogenomics - Prognosis Based on Genomics37
- Cancer Screening & Diagnosis38
- Molecular Tests Lead the Way for Cancer IVD MarketGrowth39
- Table 5: Worldwide Cancer Diagnostic Testing Market(2006 - A Recent Past
Review): Percentage Breakdownof Value Sales for Immunoassays, Histology
(IHC/ISH),Pap Testing, Flow Cytometry, Prostate-Specific Antigen, Molecular
Assays, and Fecal Occult Blood Test(includes corresponding Graph/Chart)39
- Other Testing Applications40
8. PRODUCT DEVELOPMENTS/INTRODUCTIONS 41
- Life Technologies Unveils ViralSEQTM VesivirusDetection Kit41
- Applied Biosystems New Forensic DNA Kits41
- Quest Diagnostics Launches ColoVantage(tm) Test41
- QIAGEN Introduces CE-labeled KRAS Kit42
- Roche Introduces Cobas 480042
- bioMerieux Launches Upgraded Version of NucliSENSEasyQ(r) Influenza A/B
Test43
- bioMerieux Introduces NucliSENS EasyQ(r) MRSA43
- Roche Launches AMPLILINK 3.3 Series Softwareand cobas p 630 Instrument43
- Applied Biosystems Unveils 3500 Series and 3500 DXSeries Genetic Analyzer44
- Prometheus Laboratories Introduces New Range ofCancer Diagnostic Products44
- Sequenom Introduces SensiGene Cystic Fibrosis CarrierScreening Test45
- Triplex and MedMira to Unveil New Rapid Tests45
- Applied Biosystems to Introduce New Range ofTaqMan(r) PCR Assays45
- Quest Diagnostics Unveils HIV-1 Coreceptor Tropism Test46
- Luminex introduced New Range of Cystic Fibrosis Tests46
- bioMerieux Introduces VIDAS(r) EBV Test46
- Luminex Unveils Two Novel Cystic Fibrosis Tests47
- MEDomics Launches MitoDx(tm) for DiagnosingMitochondrial Diseases47
- Exagen Diagnostics Unveils eXaIBStest and eXaIBDBlood Tests48
- bioMerieux Introduces NucliSENS EasyQ(r) HIV-1 v2.0 Test48
- PreAnalytiX Introduces PAXgene(r) Blood miRNA Kit48
- ViraCor Laboratories Introduces New JCV Test48
- ViraCor Laboratories Rolls Out JC Virus Detection Test49
- Focus Diagnostics Laboratory Introduces PCR Test49
- Siemens Launches CLINITEK AUWi Urine Analyzing System49
- Ocimum Biosolutions to Introduce New H1N1 VirusDetection Test50
- Myriad Genetics Introduces OnDose for Cancer Diagnosis50
- Applied Biosystems Introduces TaqMan(r) Array GeneSignature Plates50
- GeneNews to Develop Blood-Based Diagnostic Tests51
- Seegene Rolls Out Seeplex(r) Diarrhea ACE Detection Test51
- Seegene Unveils Seeplex(r) Meningitis ACE Detection test51
- Cepheid Introduces Xpert MRSA/SA Nasal Diagnostic Test52
- Roche to Launch LightCycler Test52
- Xenomics Unveils New Technology for Analyzing InVivo Cell Death52
- bioMerieux Unveils NucliSENS EasyQ(r) HPV MolecularAnalytical Test53
- Xenomics to Introduce Innovative Gender Prediction Test53
- Evogen Unveils New EvoCyclerTM HD12 MolecularDiagnostics System53
- Siemens Healthcare Launches Innovance Antithrombin Test54
- Rosetta Genomics Launches miRview(tm) mesoDiagnostic Test54
- ViraCor Laboratories Introduces Cytomegalovirus AntiviralResistance Test55
- Abbott Launches Diagnostic Test for HPV Detection55
- Pathwork Diagnostics Introduces Tissue of Origin Test55
- Evogen to Offer Diagnostic Tests56
- Axial Unveils a Test for Detecting AIS56
- Myriad Introduces Prezeon56
- Exiqon Launches Test for Colon Cancer57
- Siemens Launches Diagnostic Tests for Testing Viral Load57
- QIAGEN Launches a Molecular Test for Testing theK-ras Gene57
- Spartan Launches DX-12 DNA Analyzer58
- ViraCor Introduces an Assay for Fungal Infections58
- Illumina Introduces mRNA-Seq58
- QIAGEN Rolls Out a New Diagnostic Test for AIDS58
- QIAGEN Introduces miScript miRNA Inhibitors(r) andmiScript miRNA Mimics(r)
Test Technologies59
- QIAGEN Introduces New Kits for Gene Expression andFunction Analysis59
- QIAGEN Introduces New Products in EpiTect Product Line60
- QIAGEN Launches QIAsymphony(r) Novel Modular Platform60
- Q Chip Introduces ReaX(tm) PCR Beads61
- ViraCor Rolls Out a New Test for Detecting Enterovirus61
- TMD Rolls Out New Tests for Colorectal Cancer61
- Gen-Probe Unveils APTIMAR(r) HPV Tests in Europe61
- Genzyme Genetics Introduces KRAS Mutation Analysis62
- China Medical Develops a Test for Prostate Cancer62
- Palex Medical to Introduce SoftPAP(tm)62
9. PRODUCT INTRODUCTIONS IN THE RECENTPAST - A PERSPECTIVE BUILDER 63
- TMD Launches Test for K-ras Mutations in ColorectalCancer Patients63
- CombiMatrix Releases Updated Version of ConstitutionalGenetic Array Test63
- Myriad Introduces TheraGuide 5-FU63
- CMDX Unveils First HemeScan(tm) Prognostic63
- CombiMatrix Introduces HemeScan(tm) MDS63
- Genzyme Rolls Out Two New Molecular Tests64
- Dade Behring Launches The Quadriga BeFree64
- BD Diagnostics Introduces The BD Viper System64
- Genzyme Introduces P53 Mutation Analysis64
- CombiMatrix Molecular Diagnostics Rolls OutA New Melanoma Test64
- Qiagen Launches Fast Cycling PCR Product Line65
- Genzyme Releases Molecular Assay for ColorectalCancer Patients65
- Roche Diagnostics Launches LightCycler 480 System65
- Roche Diagnostics Introduces AmpliChip CYP450 Test65
- SEQUENOM Unveils iPLEX(tm)65
- SEQUENOM Develops a Novel Process65
- Cerner Corp Develops Cerner Millennium(R) PathNetHelix (TM)66
- Roche Diagnostics Launches Amplicor HPV Test66
- Gen-Probe Launches Procleix Ultrio Assay in Europe66
- Gen-Probe Launches TIGRIS(r)DTS(tm) System66
- BD Biosciences Introduces BD QZyme(tm) Assay66
- Epoch Biosciences Releases MGB Eclipse(tm)66
- QIAGEN Unveils BioRobot MDx DSP Device66
- Digene Unveils DNAwithPap67
- Exact Sciences Launches Non-Invasive Test for ColorectalCancer67
- TDT Introduces GCC-B1 Blood Test to Detect ColorectalCancer67
- AcroMetrix Joins Hands with Nabi to Introduce ViroSure67
- Orchid Cellmark Introduces DNA Express Service67
- Roche Develops New IVD Real-Time PCR Instrument68
- Nanogen Rolls Out First Ever ASR68
- Digene Introduces Hybrid Capture68
- Digene' s Hybrid Capture 2 HPV DNA Test to EffectivelyIdentify Cervical
Cancer68
- PGD to Eliminate Human Eggs Affected with Alzheimer' sDisease68
- Esoterix Introduces New HCV Testing Program68
- Gen-Probe Releases New APTIMA Combo 2 Assay69
- Nycomed' s NeoSpect to Identify Suspected Lung Cancer69
- DNAPrint Introduces New Services to AssistForensic Market69
- IMBG Develops an Efficient Procedure to Treat Diseases69
10. RECENT INDUSTRY ACTIVITY 70
- Life Technologies Obtains IVD Marking for 7500 FastDx PCR Instrument70
- Xenomics Changes Name to TrovaGene70
- Abbott and GSK Team Up in the Area of MolecularDiagnosis70
- Asuragen Enters Into Collaborations for PancreaticCancer Tests71
- Transgenomic Licenses Intellectual Property fromIntegragen71
- Health Discovery Inks Agreement with Pancreas, Biliaryand Liver Surgery
Center of New York71
- Qiagen Enters into Agreement with Celera72
- The Tecan Group Inks Agreement with Enigma72
- AdnaGen AG and TATAA Molecular Diagnostics InksAgreement72
- Northeast Pharmaceuticals to Establish BiopharmaJV with Shenyang72
- Wescor Divests Microarray Technology Related Assetsto Gamida For Life
Group73
- Predictive Biosciences Takes Over OncoDiagnosticLaboratory73
- Applied Biosystems Obtains Approval for AmpFlSTR(r)MiniFiler(tm) PCR
Amplification Kit74
- Life Technologies Acquires AcroMetrix74
- Ipsogen SA and The Institut Curie Enters into ScientificCollaboration
Agreement74
- bioTheranostics and Ferrer inCode Enters into CommercialAgreement74
- Quidel Corp Signs Definitive Agreement to PurchaseDiagnostic Hybrids75
- Abbott Obtains CE Marking for New Diagnostic Test75
- Transgenomic Enters into Licensing Agreement withGene Solutions75
- QIAGEN Acquires SABiosciences76
- Corgenix Medical and BG Medicine Inks SupplyAgreement76
- Roche receives FDA Approval for Additional Usage ofcobas(r) TaqScreen MPX
Test76
- Gen-Probe Obtains FDA Approval for Marketing ofProParaflu+TM Assay77
- bioMerieux Enters into Agreement with GSK77
- Tecan Group and Hologic Sign Agreement77
- QIAGEN Takes Over DxS78
- Tyrian Ends Partnership with Becton, Dickinson and Co78
- Becton, Dickinson and Co to Purchase HandyLab78
- Quidel and BioHelix Enter into Agreement79
- Gen-Probe to Take Over Prodesse79
- Summit Partners Acquires Stake in ApoCell80
- Merck to form Alliance with QIAGEN80
- Gen-Probe to Spin Off Industrial Testing Assets80
- ImClone Systems and Bristol-Myers Squibb Enter intoCollaboration with DxS80
- Danaher to Acquire A Joint Venture Company81
- Abbott Enters into Alliance with Pfizer for MolecularDiagnostic Test81
- Rosetta and Warnex Ink Distribution Agreement81
- ViraCor Laboratories Merges with IBT Laboratories82
- ELITech Takes Over Assets of Nanogen82
- LabCorp Signs Definitive Agreement with MonogramBiosciences82
- Axial Biotech and University of Utah Enter intoCollaboration82
- Celera and Bayer Schering Pharma Sign LicensingAgreement83
- AVESTHAGEN Enters into Collaboration with VTTTechnical Research Centre83
- 3M Terminates Collaboration Agreement with Gen-Probe83
- BioGenex and Abbott Expand Joint Development andDistribution Agreement84
- Pfizer Extends Collaboration Agreement with MonogramBiosciences84
- BD Diagnostics Inks Agreement with HandyLab84
- TriLink BioTechnologies and Osmetech MolecularDiagnostics Ink Agreement85
- PerkinElmer Buys Analytica of Branford85
- Ipsogen Signs Agreement with Arup Laboratories86
- Prometheus Laboratories and Rosetta Genomics InkAgreement86
- AMDL and Precision Diagnostic Laboratory SignsAgreement86
- Osmetech Signs Agreement with Fisher HealthCare87
- Interleukin Genetics Inks Licensing Agreement withLABEC Pharma87
- deCODE Genetics Inks Licensing Agreements with Celera87
- Nuvera Biosciences Signs Licensing Agreement withVeridex87
- GE Healthcare Inks Research Agreement with Brighamand Women' s Hospital88
- Gen-Probe Purchases Tepnel Life Sciences88
- AdnaGen AG Receives US Patent88
- Agilent Technologies Selects Asuragen as CertifiedService Provider88
- Genstruct Enters into Partnership with Gene Logic89
- Lab21 Takes Over Biotec Laboratories89
- ProGenTech and Innovative Biosensors Jointly SignExtension Agreement89
- Nanogen Signs and Scandinavian Gene Synthesis InksAgreement90
- Health Discovery Corporation Inks Licensing Agreementwith Abbott90
- BD Diagnostics Receives CE Marking for AmplifiedDNA Assays90
- Transgenomic Signs Licensing AgreementPower3 Medical Products91
- Rubicon Genomics and Abbott Enter into LicensingAgreement91
- Novartis Extends Collaboration with Gen-Probe91
- Eurogentec Receives ISO-Certification for IVDOligonucleotides92
- Dako and OSI Pharmaceuticals Enter into Collaboration92
- Combimatrix Molecular Diagnostics and Lenetix Enterinto Partnership92
- Sequenom to Acquire AttoSense(tm) Tests of SensiGen93
- Epigenomics AG and Sysmex Ink Research andDevelopment Collaboration Deal93
- Gene Express and Biogenuix Medsystems SignsDistribution Agreement93
- Gene Express and Funakoshi Enter into DistributionAgreement94
- BD and Company Obtains FDA Approval forMarketing GeneOhm(tm) Cdiff Test94
- XDx and Bristol-Myers Squibb Company SignsCollaborative Agreement94
- Rosetta Genomics and Teva Pharmaceutical IndustriesSigns Distribution
Agreement95
- ProGenTech Inks Deal with Center for Disease Controland Prevention in
China95
- National Jewish Health Signs Agreement with LaboratoryCorporation of
America Holdings96
- DxS and Amgen Ink Agreement96
- Enigma Diagnostics Inks Term Sheet with RocheMolecular Systems96
- Quintiles Transnational Purchases Targeted MolecularDiagnostics97
- Invitrogen Merges with Applied Biosystems97
- Gen-Probe Receives CE-Mark for APTIMA(r) HPV Test97
- BD Receives Health Canada Licensing for BDGeneOhm(tm) Cdiff Molecular
Assay98
- Abbott Molecular and Epigenomics Amend LicensingAgreement98
- Nanogen Inks Agreement with A. Menarini Diagnostics98
- EraGen Biosciences Signs Distribution Agreement withInter Medico99
- Spartan Bioscience Enters into Agreement with NorDiag99
- Celera and Nanogen Extend License Agreement99
- NorDiag and Molzym Enter Into Collaboration andDistribution Agreements100
- ZyGEM Inks Agreement with Advalytix Products100
- Response Genetics and NeoGenomics Laboratories Enterinto Agreement100
- SIRS-Lab Obtains Certification for Quality Managementof In-Vitro
Diagnostics100
- China Medical and Molecular Diagnostics TechnologiesInk Agreement101
- QIAGEN Takes Over Entire Assets of BiosystemsDivision of Biotage102
- Cepheid Secures FDA Approval for Xpert(tm) Test102
- Osmetech Signs Agreement with Qiagen102
- Luminex Enters into Agreement with BD Diagnostics102
- bioMerieux Acquires AviaraDx103
- Pall Takes Over GeneSystems103
- Corgenix Medical and BG Medicine Ink Agreement104
- Diatherix Laboratories Receives CLIA Certificate104
- Novartis Diagnostics Secures FDA Authorization forPROCLEIX(r) ULTRIO(r)
Assay104
- Bio-Reference Laboratories to Start K-ras Mutation Testing105
- Hologic Purchases Third Wave Technologies105
- Asuragen and Affymetrix Ink an Agreement105
- Health Discovery and DCL Medical Laboratories Sign anAgreement106
- Osmetech Receives the US Food and Drug AdministrationClearance106
- BD Diagnostics Secures CE Marking for BDGeneOhmTM Cdiff molecular Test107
- Siemens Healthcare Diagnostics Secures CE-MarkingApproval107
- QIAGEN Takes Over Corbett Life Science107
- QIAGEN Obtains CE Mark Approval for Borrelia andHIV PCR Kits108
- Gen-Probe Receives License from Xceed Molecular108
- Nanogen Bags Contract from US Centers for DiseaseControl and Prevention109
- Gen-Probe to Take Over Innogenetics109
- Third Wave Technologies to Buy Intellectual Property109
- Prodesse and Quidel Sign an Agreement109
- Siemens Healthcare Diagnostics Licenses CertainTesting Rights110
- bioMerieux Signs MoU with Foundation for InnovativeNew Diagnostics110
- QIAGEN Collaborates with GENEART110
- Agilent Technologies and Agendia to Enter into Partnership111
- Siemens Inks Non-Exclusive Deal with LaboratoryCorporation of America(r)
Holdings111
- BD Diagnostics Receives CE-Marking for BDGeneOhm(tm) VanR Test111
- Health Discovery Completes Trials on MolecularDiagnostic Test on Prostate
Cancer111
- Gen-Probe and Agreement DiagnoCure Amends 2003License Agreement112
- OccuLogix Purchases Remaining Stake in OcuSense112
- Thermo Fisher Scientific Signs Agreement with Nanogen113
- DCL Medical Laboratories and Third Wave TechnologiesEnter into
Partnership113
- Gen-Probe Commences Clinical Trial of APTIMA(r) Assay113
- Immucor to Buy BioArray Solutions114
- Epigenomics Partners with Abbott Molecular114
- Hitachi High-Technologies and bioMerieux Enter intoPartnership115
- Luminex Molecular Diagnostics Signs Agreement withAbbott115
- Abbott Signs Agreement with OSI Pharmaceuticals,Roche and Genentech115
- Exiqon Takes Over Oncotech115
- Siemens Secures FDA Authorization for VERSANT(tm) 440Molecular System116
- Vermillion, Johns Hopkins Ink Agreements to DevelopMolecular Diagnostic
Tests116
- Beckman Coulter Inks Licensing Agreements withNational University of
Ireland116
11. CORPORATE ACTIVITY IN THE RECENT PAST -A PERSPECTIVE BUILDER 117
- Roche Takes over BioVeris117
- Siemens Acquires Dade Behring117
- DiagnoCure Acquires Catalyst Oncology117
- Burrill & Co Takes over Expression Diagnostics117
- Solis Acquires Bertrand117
- ParagonDx LLC Acquires Gentris Diagnostics118
- Beckman Collaborates to Discover CVD Symptoms118
- Exiqon to Take over Oncotech118
- Roche to Acquire Ventana118
- Qiagen Merges with Digene118
- Qiagen & Bio One Capital Collaborates119
- AGT & MAL Signs MoU119
- Qiagen Obtains Licenses to Real-Time PCR119
- Cepheid Acquires Sangtec119
- Source MDx Collaborates with Pfizer119
- Nanosphere Receives FDA Clearance for SecondMolecular Diagnostic Test120
- QIAGEN Acquires eGene120
- Quest Diagnostics Acquires AmeriPath120
- Mayo and ILMN Team up to Develop MolecularDiagnostics for Complex
Diseases120
- CHEO and ILMN Team up to Develop MolecularDiagnostics for Newborn
Screening120
- Siemens Medical Solutions USA Sets Up SiemensMedical Solutions
Diagnostics121
- Novartis Acquires Chiron121
- Quest Diagnostics Acquires Focus Diagnostics121
- Becton Dickinson Acquires GeneOhm121
- Iris International Acquires Leucadia Technologies121
- Predicant Biosciences Acquires Pathwork Informatics121
- AmeriPath Acquires Rose Pathology Associates122
- Nanogen Acquires Amplimedical' s Diagnostics Division122
- Nanogen Acquires Immunoassay Test Business of SpectralDiagnostics122
- Fisher Scientific Acquires Athena122
- Qiagen Acquires Genaco122
- Bio-Rad Acquires Blackhawk BioSystems122
- IRIS International Acquires Leucadia Technologies122
- Qiagen Acquires Shenzhen PG Biotech123
- Qiagen Acquires Artus GmbH123
- Nanogen and Fisher Increases Agreement Tenure123
- Qiagen Signs An Agreement with Gentra123
- Qiagen Inks an Agreement with VLA123
- Stratagene Signs an Agreement with AROS124
- Bayer Inks an Agreement with Hamilton Company124
- Prodesse and Invitrogen Sign a Pact124
- Illumina Forms Collaboration with ReaMetrix124
- PerkinElmer Signs an Agreement with Jacobi Medical124
- UniPath and Roche Diagnostics Sign an Accord124
- Qiagen Alliances with Eppendorf125
- Olympus and Cangen Extends their Research Collaboration125
- Toppan, Shimadzu and Third Wave Collaborate toDevelop A POC Molecular
Diagnostic Instrument125
- Focus Diagnostics Signs an Agreement with Stratagene125
- Innogenetics Inks an Agreement with Roche Diagnostics126
- The University of Goettingen, Bruker Daltonik andPANATecs Collaborate to
Develop New MolecularDiagnostic Assays for Rheumatoid Arthritis126
- Focus Diagnostics Enters into an Agreement with Luminex126
- QIAGEN Expands Strategic Alliance with Protedyne126
- Specialty Laboratories Teams Up with SEQUENOMand Siemens126
- Gen-Probe Enters into a Licensing Agreement with Corixa127
- Gen-Probe Inks a Supply and Purchase Agreement withF. Hoffmann-La Roche127
- Gen-Probe Enters into a Licensing Agreement withAdnaGen127
- Roche Establishes New Polymerase Chain Reaction (PCR)Manufacturing
Center127
- Ambion Establishes a Subsidiary in Japan127
- Gen-Probe Gains FDA Approval for APTIMA(r)127
- Blood Center of Southeastern Wisconsin Adopts Ambion' sSignature(tm) CF 2.0
ASR128
- Orchid Biosciences, Inc. Becomes Orchid Cellmark Inc128
- Roche Acquires IGEN International128
- GE Takes Over Amersham Plc128
- Nanogen Acquires SYN - X PHARMA128
- Nanogen Merges with Epoch Biosciences128
- Sequenom Enters into Collaboration with Siemens129
- TMD Joins Hands with University of Texas129
- GE Global and Two other Companies Enters into a JointResearch
Collaboration129
- Third Wave and BML Extend Partnership to PromoteMolecular Diagnostic
Tests129
- ViroLogic Signs an Agreement with ACLARA129
- Abbott and BioGenex Sign an Agreement129
- Novation Signs a Pact with Bayer Diagnostics130
- Osmetech Enters into a Licensing Agreement with LGCLimited130
- Licensing Agreement between DxS Ltd and SangtecMolecular Diagnostics130
- EraGen Biosciences Strikes a Deal with Inter Medico130
- Nanogen Bags Patent for Molecular Diagnostics andOptical Waveguides
Systems130
- Gen-Probe Secures Regulatory Approval for PROCLEIX (r)ULTRIO(tm) Assay130
- Gen-Probe Bags FDA Approval to Use TIGRIS DTSSystem for STD Testing131
- Gen-Probe Acquires Majority Stake in MLT131
- AmeriPath in Strategic Alliance with Roche131
- Abbott and Promega to Offer Nucleic Acid ExtractionProducts131
- Ambion RNA to Offer Services Through BBI131
- STMicroelectronics Inks an Agreement with Mobidiag132
- BBI Contracts with IDS132
- Focus to Assist FDA in Evaluation of AntimicrobialResistance132
- Bayer Acquires Rights to Detect HCV and HIV Antibodies132
- Cenetron in Strategic Alliance with Roche132
- Saint Luke' s Health System in Alliance with Roche133
- US LABS Adds Gene Expression Profiling Capabilitieson (FFPE) Tissue133
- Bayer Acquires Visible Genetics133
- Qiagen Enters into an Agreement with RMS133
- Dabur Starts a New Molecular Diagnostic Lab133
- Roche Gains Rights for Cervical-Cancer Testing Market134
- Ventana Acquires License From MDI134
- Genzyme Genetics Gains Rights for Genzyme Molecular' sCancer Diagnostics134
- Abbott in Strategic Alliance with Celera134
- MDI and DiagnoCure Join Hands to IntegrateImmunoCyt/uCyt with InPath134
- MDI and PMI to Jointly Promote Lung Cancer DetectionSystem135
- MDI in Agreement with Esoterix135
- MDI to Expand Product Base in China135
- Abbott and Tecan to Offer Devices for MolecularDiagnostic Assays135
- Invirion Extends Licensing Agreement with MDI135
- Ambion RNA Grants License to Celera136
- Morewood and IT&M to Introduce New Micro ArraySystem136
- Ambion RNA Constructs New Manufacturing Facility136
- LabCorp Teams up with Celera136
- Athena Launches New DNA Testing for TSC136
- Genezyme Genetics Expands Cancer Testing Services137
- Promega Teams Up with Abbott137
- ChromaVision and Ventana Join Hands to MarketTesting Process that
Identifies HPV137
- OraSure in Agreement with Abbott137
- Nanogen and Bionomics to Jointly Develop IVD forEpilepsy137
- DiagnoCure and Compugen Join Hands to DevelopTests to Identify Epithelial
Cancers137
- OraSure Gets FDA Approval for OraQuick RapidHIV-1 Test138
- Ampersand and Accumed Merged to Form MDI138
- Abbott Acquires Vysis138
- Millennium and Abbott Forge 5-Year Drug Deal138
- Bode Enters into Agreement to Undertake DNA Testing139
- BD Contracts with TriPath to Develop MolecularDiagnostics139
- TriPath Installs New Interactive System139
- Archemix in Strategic Alliance with RPI139
- AmeriPath Strengthens Relationship with GenomicsCollaborative139
12. FOCUS ON SELECT GLOBAL PLAYERS 140
- Abbott Laboratories (US)140
- Abbott Molecular140
- Applera Corp. (US)140
- Celera (US)140
- Biomerieux (France)141
- CytoCore Inc. (US)141
- ELITech Group (France)142
- GE Healthcare (US)142
- Gen-Probe, Inc. (US)143
- Genzyme Corp. (US)143
- Genzyme Genetics (US)143
- MiraiBio, Inc. (US)144
- Novartis Vaccines & Diagnostics, Inc. (US)144
- QIAGEN N.V (The Netherlands)144
- Quest Diagnostics, Inc. (USA)145
- Roche Diagnostics (Switzerland)145
- Siemens Healthcare Diagnostics (US)146
- Tecan Group Ltd. (Switzerland)146
13. GLOBAL MARKET PERSPECTIVE 147
- Table 6: World Recent Past, Current & Future MarketAnalysis for Molecular
Diagnostics by GeographicRegion - US, Canada, Japan, Europe,
Asia-Pacific(excluding Japan) and Rest of World IndependentlyAnalyzed with
Annual Sales Figures in US$ Millionfor Years 2007 through 2015
(includescorresponding Graph/Chart)147
- Table 7: World Historic Review for Molecular Diagnosticsby Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of
World Independently Analyzed with Annual Sales Figures in US$ Million forYears
2000 through 2006 (includes correspondingGraph/Chart)148
- Table 8: World 11-Year Perspective for MolecularDiagnostics by Geographic
Region - PercentageBreakdown of Dollar Sales for US, Canada, Japan,Europe,
Asia-Pacific (excluding Japan) and Rest ofWorld Markets for Years 2005, 2010 &
2015(includes corresponding Graph/Chart)149
- Table 9: World Recent Past, Current & Future MarketAnalysis for Molecular
Diagnostics (Infectious DiseaseTesting) by Geographic Region - US, Canada,
Japan,Europe, Asia-Pacific (excluding Japan), and Rest of World Independently
Analyzed with Annual Sales Figures inUS$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart)150
- Table 10: World Historic Review for Molecular Diagnostics (Infectious
Disease Testing) by Geographic Region - US,Canada, Japan, Europe, Asia-Pacific
(excluding Japan),and Rest of World Independently Analyzed with AnnualSales
Figures in US$ Million for Years 2000 through2006 (includes corresponding
Graph/Chart)151
- Table 11: World 11-Year Perspective for MolecularDiagnostics (Infectious
Disease Testing) by GeographicRegion - Percentage Breakdown of Dollar Sales
for US,Canada, Japan, Europe, Asia-Pacific (excluding Japan),and Rest of World
Markets for Years 2005, 2010 &2015 (includes corresponding Graph/Chart)152
- Table 12: World Recent Past, Current & Future MarketAnalysis for Molecular
Diagnostics (Pharmacogenomics)by Geographic Region - US, Canada, Japan,
Europe,Asia-Pacific (excluding Japan), and Rest of WorldIndependently Analyzed
with Annual Sales Figuresin US$ Million for Years 2007 through 2015(includes
corresponding Graph/Chart)153
- Table 13: World Historic Review for Molecular Diagnostics
(Pharmacogenomics) by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest ofWorld Independently Analyzed with
Annual Sales Figuresin US$ Million for Years 2000 through 2006 (includes
corresponding Graph/Chart)154Table 14: World 11-Year Perspective for Molecular
Diagnostics (Pharmacogenomics) by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and
Rest of World Marketsfor Years 2005, 2010 & 2015 (includes
correspondingGraph/Chart)155
- Table 15: World Recent Past, Current & Future MarketAnalysis for Molecular
Diagnostics (Cancer Screening)by Geographic Region - US, Canada, Japan,
Europe,Asia-Pacific (excluding Japan), and Rest of WorldIndependently Analyzed
with Annual Sales Figuresin US$ Million for Years 2007 through 2015(includes
corresponding Graph/Chart)156
- Table 16: World Historic Review for Molecular Diagnostics (Cancer
Screening) by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific
(excluding Japan) and Restof World Independently Analyzed with Annual Sales
Figuresin US$ Million for Years 2000 through 2006 (includes corresponding
Graph/Chart)157Table 17: World 11-Year Perspective for MolecularDiagnostics
(Cancer Screening) by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), andRest of World
Markets for Years 2005, 2010 & 2015(includes corresponding Graph/Chart)158
14. UNITED STATES 159
A. Market Analysis 159
- A Precursor to the Molecular Diagnostics Marketin the US159
- Molecular Diagnostics Heavily Tied to Proteomicsand Genomics159
- Burgeoning Potential for Genetic Testing159
- Regulatory Environment160
- Regulations Out for Molecular Diagnostic Testingof HPV160
- Limited Reimbursements - A Major Hindrance161
B. Market Analytics 161
- Table 18: The US Recent Past, Current & Future Analysis for Molecular
Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets Independently Analyzed with Annual Sales Figures
inUS$ Million for Years 2007 through 2015 (includes corresponding
Graph/Chart)161
- Table 19: The US Historic Review for Molecular Diagnostics by Application
- Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart)162
- Table 20: The US 11-Year Perspective for MolecularDiagnostics by
Application - Percentage Breakdownof Dollar Sales for Infectious Disease
Testing, Pharmacogenomics, andCancer ScreeningMarkets for 2005, 2010 &
2015(includescorresponding Graph/Chart)162
15. CANADA 163
- Market Analysis163
- Table 21: Canadian Recent Past, Current & FutureAnalysis for Molecular
Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics,
andCancer Screening Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2007through 2015 (includes corresponding
Graph/Chart)163
- Table 22: Canadian Historic Review for Molecular Diagnostics by
Application - Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales Figures inUS$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart)164Table 23: Canadian 11-Year Perspective for Molecular
Diagnostics by Application - Percentage Breakdownof Dollar Sales for
Infectious Disease Testing, Pharmacogenomics, and Cancer ScreeningMarkets for
2005, 2010 & 2015 (includescorresponding Graph/Chart)164
16. JAPAN 165
- Market Analysis165
- Table 24: Japanese Recent Past, Current & Future Analysis for Molecular
Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets Independently Analyzed with Annual SalesFigures in
US$ Million for Years 2007 through2015 (includes corresponding Graph/Chart)165
- Table 25: Japanese Historic Review for Molecular Diagnostics by
Application - Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales Figures inUS$
Million for Years 2000 through 2006 (includes corresponding Graph/Chart)166
- Table 26: Japanese 11-Year Perspective for Molecular Diagnostics by
Application - Percentage Breakdownof Dollar Sales for Infectious Disease
Testing, Pharmacogenomics, and Cancer ScreeningMarkets for 2005, 2010 & 2015
(includescorresponding Graph/Chart)166
17. EUROPE
A. Market Analysis 167
- Insight into Molecular Diagnostics Markets in Europe167
- Table 27: European Molecular Diagnostics Market by Leading Players (2008)
- Market Shares of Leading Players by Value Sales for Roche Diagnostics,
Abbott Diagnostics, Bayer Diagnostics, Becton Dickinson,Digene Diagnostics,
BioMerieux, and Others(includes corresponding Graph/Chart)168
B. Market Analytics 169
- Table 28: European Recent Past, Current & Future Analysis for Molecular
Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of
Europe Markets Independently Analyzed with Annual Sales Figuresin US$ Million
for Years 2007 through 2015(includes corresponding Graph/Chart)169
- Table 29: European Historic Review for Molecular Diagnostics by Geographic
Region - France, Germany,Italy, UK, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Millionfor Years 2000 through 2006
(includes corresponding Graph/Chart)170
- Table 30: European 11-Year Perspective for Molecular Diagnostics by
Geographic Region - PercentageBreakdown of Dollar Sales for France,
Germany,Italy, UK, and Rest of Europe Markets forYears 2005, 2010 & 2015
(includescorresponding Graph/Chart)171
- Table 31: European Recent Past, Current & Future Analysis for Molecular
Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets Independently Analyzed with Annual SalesFigures in
US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)172
- Table 32: European Historic Review for Molecular Diagnostics by
Application -Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales Figures inUS$
Million for Years 2000 through 2006 (includes corresponding Graph/Chart)173
- Table 33: European 11-Year Perspective for Molecular Diagnostics by
Application - Percentage Breakdownof Dollar Sales for Infectious Disease
Testing, Pharmacogenomics and Cancer Screening Marketsfor Years 2005, 2010 &
2015 (includescorresponding Graph/Chart)174
17a. FRANCE 175
- Market Analysis175
- Table 34: French Recent Past, Current & Future Analysisfor Molecular
Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and
CancerScreening Markets Independently Analyzed withAnnual Sales Figures in US$
Million for Years2007 through 2015 (includes correspondingGraph/Chart)175
- Table 35: French Historic Review for MolecularDiagnostics by Application -
Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart)176
- Table 36: French 11-Year Perspective for Molecular Diagnostics by
Application - Percentage Breakdownof Dollar Sales for Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening Marketsfor 2005, 2010 & 2015
(includes correspondingGraph/Chart)176
17b. GERMANY 177
- Market Analysis177
- Table 37: German Recent Past, Current & FutureAnalysis for Molecular
Diagnostics by Application -Infectious Disease Testing, Pharmacogenomics,
andCancer Screening Markets Independently Analyzedwith Annual Sales Figures in
US$ Millionfor Years 2007 through 2015 (includescorresponding Graph/Chart)177
- Table 38: German Historic Review for MolecularDiagnostics by Application -
Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart)178
- Table 39: German 11-Year Perspective for Molecular Diagnostics by
Application - Percentage Breakdownof Dollar Sales for Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening Marketsfor 2005, 2010 & 2015
(includes correspondingGraph/Chart)178
17c. ITALY 179
- Market Analysis179
- Table 40: Italian Recent Past, Current & Future Analysis for Molecular
Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and
Cancer ScreeningMarkets Independently Analyzed with Annual SalesFigures in US$
Million for Years 2007 through2015 (includes corresponding Graph/Chart)179
- Table 41: Italian Historic Review for MolecularDiagnostics by Application
- Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2000
through 2006 (includes corresponding Graph/Chart)180
- Table 42: Italian 11-Year Perspective for Molecular Diagnostics by
Application - Percentage Breakdown of Dollar Sales for Infectious Disease
Testing, Pharmacogenomics, and Cancer Screening Markets for 2005, 2010 & 2015
(includes corresponding Graph/Chart)180
17d. UNITED KINGDOM 181
- Market Analysis181
- Table 43: The UK Recent Past, Current & Future Analysisfor Molecular
Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and
CancerScreening Markets Independently Analyzed with AnnualSales Figures in US$
Million for Years 2007 through2015 (includes corresponding Graph/Chart)181
- Table 44: The UK Historic Review for Molecular Diagnostics by Application
- Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$ Million for Years
2000through 2006 (includes corresponding Graph/Chart)182Table 45: The UK
11-Year Perspective for Molecular Diagnostics by Application - Percentage
Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics,and
Cancer Screening Markets for 2005, 2010 & 2015(includes corresponding
Graph/Chart)182
17e. REST OF EUROPE 183
- Market Analysis183
- Table 46: Rest of European Recent Past, Current & Future Analysis for
Molecular Diagnostics by Application - Infectious Disease Testing,
Pharmacogenomics, andCancer Screening Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007through 2015 (includes
corresponding Graph/Chart)183
- Table 47: Rest of European Historic Review for Molecular Diagnostics by
Application - Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales Figuresin US$
Million for Years 2000 through 2006(includes corresponding Graph/Chart)184
- Table 48: Rest of European 11-Year Perspective forMolecular Diagnostics by
Application - Percentage Breakdown of Dollar Sales for Infectious
DiseaseTesting, Pharmacogenomics, and Cancer ScreeningMarkets for 2005, 2010 &
2015 (includescorresponding Graph/Chart)185
18. ASIA-PACIFIC 186
A. Market Analysis 186
- Indian Diagnostic Market186
B. Market Analytics 186
- Table 49: Asia-Pacific Recent Past, Current & Future Analysis for
Molecular Diagnostics by Application - Infectious Disease Testing,
Pharmacogenomics,and Cancer Screening Markets IndependentlyAnalyzed with
Annual Sales Figures in US$Million for Years 2007 through 2015
(includescorresponding Graph/Chart)186
- Table 50: Asia-Pacific Historic Review for Molecular Diagnostics by
Application - Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales Figures inUS$
Million for Years 2000 through 2006 (includes corresponding Graph/Chart)187
- Table 51: Asia-Pacific 11-Year Perspective for Molecular Diagnostics by
Application - Percentage Breakdownof Dollar Sales for Infectious Disease
Testing, Pharmacogenomics, and Cancer ScreeningMarkets for 2005, 2010 & 2015
(includescorresponding Graph/Chart)188
19. REST OF WORLD 189
- Market Analysis189
- Table 52: Rest of World Recent Past, Current & Future Analysis for
Molecular Diagnostics by Application - Infectious Disease Testing,
Pharmacogenomics, andCancer Screening Markets Independently Analyzedwith
Annual Sales Figures in US$ Million forYears 2007 through 2015
(includescorresponding Graph/Chart)189
- Table 53: Rest of World Historic Review for Molecular Diagnostics by
Application - Infectious Disease Testing, Pharmacogenomics and Cancer
Screening Markets Independently Analyzed with Annual Sales Figuresin US$
Million for Years 2000 through 2006(includes corresponding Graph/Chart)190
- Table 54: Rest of World 11-Year Perspective forMolecular Diagnostics by
Application - Percentage Breakdown of Dollar Sales for Infectious
DiseaseTesting, Pharmacogenomics, and Cancer ScreeningMarkets for 2005, 2010 &
2015 (includescorresponding Graph/Chart)191
COMPETITION
|
 |
